Federal Trade Commission V Actavis Inc And Reverse Payment Or Pay For Delay Settlements
Download Federal Trade Commission V Actavis Inc And Reverse Payment Or Pay For Delay Settlements full books in PDF, epub, and Kindle. Read online free Federal Trade Commission V Actavis Inc And Reverse Payment Or Pay For Delay Settlements ebook anywhere anytime directly on your device. Fast Download speed and no annoying ads. We cannot guarantee that every ebooks is available!
Author | : Herbert HOVENKAMP |
Publisher | : Harvard University Press |
Total Pages | : 392 |
Release | : 2009-06-30 |
Genre | : Law |
ISBN | : 9780674038820 |
After thirty years, the debate over antitrust's ideology has quieted. Most now agree that the protection of consumer welfare should be the only goal of antitrust laws. Execution, however, is another matter. The rules of antitrust remain unfocused, insufficiently precise, and excessively complex. The problem of poorly designed rules is severe, because in the short run rules weigh much more heavily than principles. At bottom, antitrust is a defensible enterprise only if it can make the microeconomy work better, after accounting for the considerable costs of operating the system. The Antitrust Enterprise is the first authoritative and compact exposition of antitrust law since Robert Bork's classic The Antitrust Paradox was published more than thirty years ago. It confronts not only the problems of poorly designed, overly complex, and inconsistent antitrust rules but also the current disarray of antitrust's rule of reason, offering a coherent and workable set of solutions. The result is an antitrust policy that is faithful to the consumer welfare principle but that is also more readily manageable by the federal courts and other antitrust tribunals.
Author | : Robin Feldman |
Publisher | : Cambridge University Press |
Total Pages | : 165 |
Release | : 2017-06-09 |
Genre | : Law |
ISBN | : 131673949X |
While the shockingly high prices of prescription drugs continue to dominate the news, the strategies used by pharmaceutical companies to prevent generic competition are poorly understood, even by the lawmakers responsible for regulating them. In this groundbreaking work, Robin Feldman and Evan Frondorf illuminate the inner workings of the pharmaceutical market and show how drug companies twist health policy to achieve goals contrary to the public interest. In highly engaging prose, they offer specific examples of how generic competition has been stifled for years, with costs climbing into the billions and everyday consumers paying the price. Drug Wars is a guide to the current landscape, a roadmap for reform, and a warning of what is to come. It should be read by policymakers, academics, patients, and anyone else concerned with the soaring costs of prescription drugs.
Author | : Barry E. Hawk |
Publisher | : |
Total Pages | : 0 |
Release | : 2011 |
Genre | : |
ISBN | : |
Author | : |
Publisher | : DIANE Publishing |
Total Pages | : 129 |
Release | : 2002 |
Genre | : |
ISBN | : 1428951938 |
Author | : |
Publisher | : |
Total Pages | : 138 |
Release | : 1947 |
Genre | : |
ISBN | : |
Author | : Phillip Areeda |
Publisher | : |
Total Pages | : 80 |
Release | : 1978 |
Genre | : Antitrust law |
ISBN | : |
Author | : National Academies of Sciences, Engineering, and Medicine |
Publisher | : National Academies Press |
Total Pages | : 235 |
Release | : 2018-03-01 |
Genre | : Medical |
ISBN | : 0309468086 |
Thanks to remarkable advances in modern health care attributable to science, engineering, and medicine, it is now possible to cure or manage illnesses that were long deemed untreatable. At the same time, however, the United States is facing the vexing challenge of a seemingly uncontrolled rise in the cost of health care. Total medical expenditures are rapidly approaching 20 percent of the gross domestic product and are crowding out other priorities of national importance. The use of increasingly expensive prescription drugs is a significant part of this problem, making the cost of biopharmaceuticals a serious national concern with broad political implications. Especially with the highly visible and very large price increases for prescription drugs that have occurred in recent years, finding a way to make prescription medicinesâ€"and health care at largeâ€"more affordable for everyone has become a socioeconomic imperative. Affordability is a complex function of factors, including not just the prices of the drugs themselves, but also the details of an individual's insurance coverage and the number of medical conditions that an individual or family confronts. Therefore, any solution to the affordability issue will require considering all of these factors together. The current high and increasing costs of prescription drugsâ€"coupled with the broader trends in overall health care costsâ€"is unsustainable to society as a whole. Making Medicines Affordable examines patient access to affordable and effective therapies, with emphasis on drug pricing, inflation in the cost of drugs, and insurance design. This report explores structural and policy factors influencing drug pricing, drug access programs, the emerging role of comparative effectiveness assessments in payment policies, changing finances of medical practice with regard to drug costs and reimbursement, and measures to prevent drug shortages and foster continued innovation in drug development. It makes recommendations for policy actions that could address drug price trends, improve patient access to affordable and effective treatments, and encourage innovations that address significant needs in health care.
Author | : Kenneth L. Dorsney |
Publisher | : American Bar Association |
Total Pages | : 0 |
Release | : 2012 |
Genre | : Biotechnology |
ISBN | : 9781614384786 |
Examining the intersection between the statutory and regulatory scheme governing approval of generic pharmaceuticals and U.S. patent law in the context of Paragraph IV ANDA litigation, this comprehensive guide focuses on current and developing law as well as litigation strategies and tactics. This ready roadmap begins with an explanation of the Hatch-Waxman Act, its implementation, and litigation. Other topics include preparing and trying the case, post-trial issues and appeals, remedies, settlement, antitrust implications, and litigation of pharmaceuticals outside the U.S.
Author | : Barry L. Grossman |
Publisher | : BNA Books (Bureau of National Affairs) |
Total Pages | : 0 |
Release | : 2010 |
Genre | : Patent laws and legislation |
ISBN | : 9781570188862 |
"Section of Intellectual Property Law, American Bar Association."
Author | : Phillip Areeda |
Publisher | : |
Total Pages | : 1352 |
Release | : 1981 |
Genre | : Antitrust law |
ISBN | : |